Akorn (NASDAQ: AKRX) is one of 103 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Akorn to similar companies based on the strength of its risk, dividends, earnings, valuation, analyst recommendations, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Akorn and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akorn 1 8 1 0 2.00
Akorn Competitors 862 3771 6731 178 2.54

Akorn currently has a consensus price target of $30.14, indicating a potential downside of 6.68%. As a group, “Pharmaceuticals” companies have a potential upside of 22.85%. Given Akorn’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Akorn has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

74.7% of Akorn shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 28.2% of Akorn shares are owned by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Akorn and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akorn 7.79% 15.14% 6.51%
Akorn Competitors -2,534.36% -58.12% -8.09%

Earnings and Valuation

This table compares Akorn and its competitors gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Akorn $1.12 billion $184.24 million 54.75
Akorn Competitors $8.17 billion $1.09 billion 104.80

Akorn’s competitors have higher revenue and earnings than Akorn. Akorn is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Akorn has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Akorn’s competitors have a beta of 39.14, meaning that their average share price is 3,814% more volatile than the S&P 500.

Summary

Akorn competitors beat Akorn on 8 of the 13 factors compared.

About Akorn

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.